Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genzyme

- PMLiVE

Sanofi will provide manufacturing support for Pfizer/BioNTech’s COVID-19 vaccine

Sanofi is aiming to provide 100 million doses of the vaccine by the end of the year

Sanofi reception

Sanofi gains access to antibody tech with Kymab acquisition

French pharma will receive global rights to phase 2a monoclonal antibody

- PMLiVE

Two drugs found to reduce mortality in severe COVID-19 patients

Actemra and Kevzara also improved recovery times among critically ill COVID-19 patients

Biogen Idec building

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

New administration offers same efficacy as subcutaneous injection

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

- PMLiVE

Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants

Phase 2b study has been delayed to February 2021

Sanofi reception

Sanofi’s quadrivalent flu vaccine Supemtek scores EU approval

Company expects first EU launches in 2022/2023 flu season

- PMLiVE

Sanofi set to acquire Kiadis for €308m

Acquisition will see French pharma gain access to NK-cell platform

Sanofi reception

Sanofi and Translate Bio eye launch of phase 1/2 COVID-19 vaccine study

Preclinical data for mRNA-based vaccine supports clinical development

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links